Healthcare
Zealand Pharma A/S(ZLDPF)
Live Price
Offline$44.70
+0.00% today
1Y Change
-21.96%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $21.11B
- Revenue Growth
- +14565.6%
- EPS Growth
- +662.7%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zealand Pharma A/S (ZLDPF) is a Healthcare stock with a market cap of $21.11B and listed on OTC. The stock last traded around $44.70 and down 22.0% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +14565.6%, EPS growth of +662.7%, a dividend yield of 0.0%. What stands out right now is revenue +14565.6%, EPS +662.7%, free cash flow +786.9% with operating margin 75.5% and ROIC 40.6%. Valuation is more restrained than many high-expectation growth names at P/E 3.3 and price/sales 2.3. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines ZLDPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+14565.6% vs +7.6% peer median
Operating Margin
Above sector median
+75.5% vs +19.4% peer median
P/E
Below sector median
3.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 7, 2026 with an EPS surprise of +36.3% and a revenue surprise of +86.5%.
The operating story is still moving forward
Revenue is running at +14565.6% and EPS at +662.7%, with operating margin around 75.5%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | +36.3% | -1.4% | -9.9% | -9.7% |
2026 Feb 19, 2026 | +35.6% | +0.0% | -5.7% | -32.2% |
2025 Nov 13, 2025 | +18.9% | +0.0% | +3.3% | -2.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZLDPF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZLDPF Max Drawdown
-53.14%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZLDPF and SPY.
Company Overview
Zealand Pharma A/S
Other OTC
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
- Leadership
- Adam Sinding Steensberg
- IPO Date
- Feb 25, 2013
- Employees
- 385
- Street Address
- Sydmarken 11
- Mailing
- Copenhagen, 2860
- Region
- Copenhagen, DK
- Reporting Currency
- USD
- Investor Line
- 45 88 77 36 00
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 3.3
- EV/EBITDA
- 2.4
- Price/Sales
- 2.3
- Price/Book
- 1.4
Growth
- Revenue
- +14565.6%
- EPS
- +662.7%
- Free Cash Flow
- +786.9%
Profitability
- Gross Margin
- 99.8%
- Operating Margin
- 75.5%
- Net Margin
- 70.0%
- ROE
- 47.9%
- ROIC
- 40.6%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 23.57
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.